These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33713599)

  • 21. Structural Studies on the Binding Mode of Bisphenols to PPARγ.
    Useini A; Schwerin IK; Künze G; Sträter N
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
    Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
    Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
    Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data.
    Kaupang Å; Laitinen T; Poso A; Hansen TV
    Proteins; 2017 Sep; 85(9):1684-1698. PubMed ID: 28543443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.
    Brust R; Shang J; Fuhrmann J; Mosure SA; Bass J; Cano A; Heidari Z; Chrisman IM; Nemetchek MD; Blayo AL; Griffin PR; Kamenecka TM; Hughes TS; Kojetin DJ
    Nat Commun; 2018 Nov; 9(1):4687. PubMed ID: 30409975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for the activation of PPARgamma by oxidized fatty acids.
    Itoh T; Fairall L; Amin K; Inaba Y; Szanto A; Balint BL; Nagy L; Yamamoto K; Schwabe JW
    Nat Struct Mol Biol; 2008 Sep; 15(9):924-31. PubMed ID: 19172745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
    Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.
    Tsukahara T; Tsukahara R; Yasuda S; Makarova N; Valentine WJ; Allison P; Yuan H; Baker DL; Li Z; Bittman R; Parrill A; Tigyi G
    J Biol Chem; 2006 Feb; 281(6):3398-407. PubMed ID: 16321982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ.
    Shang J; Kojetin DJ
    bioRxiv; 2024 May; ():. PubMed ID: 38798544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
    Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
    Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
    Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
    Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformational Diversity of the Helix 12 of the Ligand Binding Domain of PPARγ and Functional Implications.
    Batista MR; Martínez L
    J Phys Chem B; 2015 Dec; 119(50):15418-29. PubMed ID: 26598113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
    Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
    Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An alternate binding site for PPARγ ligands.
    Hughes TS; Giri PK; de Vera IM; Marciano DP; Kuruvilla DS; Shin Y; Blayo AL; Kamenecka TM; Burris TP; Griffin PR; Kojetin DJ
    Nat Commun; 2014 Apr; 5():3571. PubMed ID: 24705063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.
    Waku T; Shiraki T; Oyama T; Maebara K; Nakamori R; Morikawa K
    EMBO J; 2010 Oct; 29(19):3395-407. PubMed ID: 20717101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.
    Mottin M; Souza PC; Ricci CG; Skaf MS
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.